BDBM50314101 (S)-N1,N5-bis((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S,32S,38aS)-17-((1H-imidazol-4-yl)methyl)-20-benzyl-3-carbamoyl-32-(4-hydroxybenzyl)-11-((R)-1-hydroxyethyl)-29-isobutyl-7,7,25,28-tetramethyl-1,9,12,15,18,21,24,27,30,33,34-undecaoxohexatriacontahydropyrrolo[2,1-g][1,2,5,8,12,15,18,21,24,27,30,33]dithiadecaazacyclohexatriacontin-8-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-yl)-2-methylpentanediamide::CHEMBL1090639

SMILES: CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CC[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O

InChI Key: InChIKey=YKZSQGCXTZLZOS-DSRPWJRPSA-N

Data: 1 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 50314101   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
IgG receptor FcRn large subunit p51 (Homo sapiens (Human))	BDBM50314101 ((S)-N1,N5-bis((S)-1-((S)-1-((3R,8R,11S,17S,20S,29S...) Show SMILES CC(C)C[C@@H]1N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CC[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC2(C)C)C(N)=O)C(C)(C)SSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(N)=O)[C@@H](C)O |r| Show InChI InChI=1S/C148H204N38O34S4/c1-80(2)58-109-137(213)169-97(60-89-45-49-93(189)50-46-89)120(198)143(219)185-56-30-42-107(185)135(211)175-105(124(149)200)76-221-223-147(8,9)122(141(217)177-118(83(6)187)139(215)159-70-112(192)166-103(66-91-68-155-78-163-91)131(207)171-99(62-85-32-20-16-21-33-85)127(203)161-72-114(194)181(12)74-116(196)183(109)14)179-133(209)101(64-87-36-24-18-25-37-87)173-129(205)95(40-28-54-157-145(151)152)165-111(191)53-44-82(5)126(202)168-96(41-29-55-158-146(153)154)130(206)174-102(65-88-38-26-19-27-39-88)134(210)180-123-142(218)178-119(84(7)188)140(216)160-71-113(193)167-104(67-92-69-156-79-164-92)132(208)172-100(63-86-34-22-17-23-35-86)128(204)162-73-115(195)182(13)75-117(197)184(15)110(59-81(3)4)138(214)170-98(61-90-47-51-94(190)52-48-90)121(199)144(220)186-57-31-43-108(186)136(212)176-106(125(150)201)77-222-224-148(123,10)11/h16-27,32-39,45-52,68-69,78-84,95-110,118-119,122-123,187-190H,28-31,40-44,53-67,70-77H2,1-15H3,(H2,149,200)(H2,150,201)(H,155,163)(H,156,164)(H,159,215)(H,160,216)(H,161,203)(H,162,204)(H,165,191)(H,166,192)(H,167,193)(H,168,202)(H,169,213)(H,170,214)(H,171,207)(H,172,208)(H,173,205)(H,174,206)(H,175,211)(H,176,212)(H,177,217)(H,178,218)(H,179,209)(H,180,210)(H4,151,152,157)(H4,153,154,158)/t82-,83+,84+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,118-,119-,122+,123+/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	5.60	n/a	n/a	n/a	n/a	n/a	n/a
Syntonix Pharmaceuticals, Inc. Curated by ChEMBL					Assay Description Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA				J Med Chem 53: 1587-96 (2010) Article DOI: 10.1021/jm901128z BindingDB Entry DOI: 10.7270/Q23R0T1H
					More data for this Ligand-Target Pair